Axsome醫療 AXSM 深 滬
已收盤 09-19 16:00:00 美东时间
94.32
+2.780
+3.04%
華盛通- 最 高95.77
- 今 開92.89
- 成交量 34.05万股
- 最 低 91.80
- 昨 收 91.54
- 總市值 44.68亿
- 52周最高 98.40
- 市盈率 靜 --
- 換手率 0.72%
- 52周最低 55.02
- 委 比 -79.98%
- 總股本 4737.44万
- 歷史最高 109.94
- 量 比 1.01
- 振 幅 4.34%
- 歷史最低 1.94
- 每 手 1
- 風險率 9.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Axsome Therapeutics (AXSM) Gets a Buy from Cantor Fitzgerald
In a report released on September 4, Charles Duncan from Cantor Fitzgerald main...
09-06 19:27
Axsome migraine therapy undergoes FDA review again
Axsome Therapeutics (NASDAQ:AXSM) announced Wednesday that the U.S. Food and Drug Administration (FDA) accepted its resubmitted marketing application for its experimental migraine therapy AXS-07. The ...
09-04 19:26
Unveiling 14 Analyst Insights On Axsome Therapeutics
Across the recent three months, 14 analysts have shared their insights on Axsom...
08-22 22:00
Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
Axsome Therapeutics (NASDAQ:AXSM) has reached an agreement with Sandoz (OTCQX:SDZNY) to dismiss the patent litigation related to Axsome’s product Sunosi (solriamfetol), it said on Wednesday. The litig...
08-21 19:51
Investors Interested In Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Revenues
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) price-to-sales (or "P/S") ratio of 14...
08-07 20:02
快讯 | Axsome Therapeutics公司: RBC将目标价从131美元下调至130美元。
Axsome Therapeutics Inc : RBC Cuts Target Price to $130 From $131
08-06 14:43
Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target
Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $130 price target.
08-06 00:57
Axsome Therapeutics Q2 2024 Adj. EPS $(1.12) Beats $(1.34) Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.12) per share which beat the analyst consensus estimate of $(1.34) by 16.42 percent.
08-05 19:12
快讯 | Axsome Therapeutics公司预计在2024年第三季度提交Axs-14用于纤维肌痛的新药申请。
Axsome Therapeutics Inc: Nda Submission for Axs-14 in Fibromyalgia Expected 3Q ...
08-05 19:03
Axsome Therapeutics Q2 Sales $87.166M Beat $86.659M Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly sales of $87.166 million which beat the analyst consensus estimate of $86.659 million by 0.58 percent. This is a 86.65 percent increase over sales of $46.700 million
08-05 19:01
